Targeting signal transduction as a strategy to treat inflammatory diseases

[1]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[2]  V. Dixit,et al.  Cryopyrin activates the inflammasome in response to toxins and ATP , 2006, Nature.

[3]  S. Akira,et al.  Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3 , 2006, Nature.

[4]  K. Papp,et al.  A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. , 2006, Journal of the American Academy of Dermatology.

[5]  H. Matsuyuki,et al.  Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. , 2006, Cellular & molecular immunology.

[6]  L. O’Neill,et al.  How Toll-like receptors signal: what we know and what we don't know. , 2006, Current opinion in immunology.

[7]  M. Mann,et al.  Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6 , 2006, Nature.

[8]  A. Shahangian,et al.  Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response , 2006, Nature.

[9]  Ki-Young Lee,et al.  TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. , 2005, Genes & development.

[10]  Jun Wang,et al.  Small-Molecule Inhibition of TNF-α , 2005, Science.

[11]  S. Akira,et al.  RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement , 2005, The Journal of experimental medicine.

[12]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[13]  Jean-Philippe Spano,et al.  Proteasome inhibition: a new approach for the treatment of malignancies. , 2005, Bulletin du cancer.

[14]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[15]  P. Moynagh,et al.  The NF-κB pathway , 2005, Journal of Cell Science.

[16]  Michael Karin,et al.  IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy , 2005 .

[17]  A. Hoffmann,et al.  Molecular Determinants of Crosstalk between Nuclear Receptors and Toll-like Receptors , 2005, Cell.

[18]  P. Parren,et al.  Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. , 2005, Arthritis and rheumatism.

[19]  T. Herdegen,et al.  Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. , 2005, Trends in pharmacological sciences.

[20]  C. Hawkey,et al.  Rdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative Colitis , 2005, Inflammatory bowel diseases.

[21]  F. Martinon,et al.  NLRs join TLRs as innate sensors of pathogens. , 2005, Trends in immunology.

[22]  C. Nickerson-Nutter,et al.  mTOR--beyond transplantation. , 2005, Current opinion in pharmacology.

[23]  C. Battram,et al.  Preclinical Profile of Ciclesonide, a Novel Corticosteroid for the Treatment of Asthma , 2005, Journal of Pharmacology and Experimental Therapeutics.

[24]  C. Dominguez,et al.  p38 MAP kinase inhibitors: many are made, but few are chosen. , 2005, Current opinion in drug discovery & development.

[25]  U. Siebenlist,et al.  Control of lymphocyte development by nuclear factor-κB , 2005, Nature Reviews Immunology.

[26]  K. Honda,et al.  Spatiotemporal regulation of MyD88–IRF-7 signalling for robust type-I interferon induction , 2005, Nature.

[27]  Dairong Wang,et al.  Cardiovascular hazard and non-steroidal anti-inflammatory drugs. , 2005, Current opinion in pharmacology.

[28]  Jong-Suk Kim,et al.  PPAR‐gamma modulates allergic inflammation through up‐regulation of PTEN , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  C. Coban,et al.  Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-α induction , 2005, The Journal of experimental medicine.

[30]  D. Trune,et al.  Identification of a Peptide Derived from Vaccinia Virus A52R Protein That Inhibits Cytokine Secretion in Response to TLR-Dependent Signaling and Reduces In Vivo Bacterial-Induced Inflammation1 , 2005, The Journal of Immunology.

[31]  J. Dancey.  Inhibitors of the mammalian target of rapamycin , 2005, Expert opinion on investigational drugs.

[32]  S. Ghosh,et al.  Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. , 2005, Arthritis and rheumatism.

[33]  Michael Karin,et al.  Nod2 Mutation in Crohn's Disease Potentiates NF-κB Activity and IL-1ß Processing , 2005, Science.

[34]  Andrea Messori,et al.  New drugs for rheumatoid arthritis [6] (multiple letters) , 2004 .

[35]  B. Aronow,et al.  Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB:p52 dimers , 2004 .

[36]  J. Dean,et al.  The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. , 2004, Cellular signalling.

[37]  A. Lindén,et al.  Interleukin-17 family members and inflammation. , 2004, Immunity.

[38]  M. Humbert.  Ciclesonide: a novel inhaled corticosteroid , 2004, Expert opinion on investigational drugs.

[39]  Domenico Spina,et al.  The potential of PDE4 inhibitors in respiratory disease. , 2004, Current drug targets. Inflammation and allergy.

[40]  Tomohiro Watanabe,et al.  NOD2 is a negative regulator of Toll-like receptor 2–mediated T helper type 1 responses , 2004, Nature Immunology.

[41]  J. O’Shea,et al.  A new modality for immunosuppression: targeting the JAK/STAT pathway , 2004, Nature Reviews Drug Discovery.

[42]  R. Fleischmann,et al.  Does safety make a difference in selecting the right TNF antagonist? , 2004, Arthritis research & therapy.

[43]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[44]  J. Kay,et al.  The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. , 2004, Rheumatology.

[45]  F. Martinon,et al.  NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. , 2004, Immunity.

[46]  C. Dinarello.  Unraveling the NALP-3/IL-1beta inflammasome: a big lesson from a small mutation. , 2004, Immunity.

[47]  Giulio Superti-Furga,et al.  A physical and functional map of the human TNF-α/NF-κB signal transduction pathway , 2004, Nature Cell Biology.

[48]  C. Jefferies,et al.  Interferon Regulatory Factor-3-mediated Activation of the Interferon-sensitive Response Element by Toll-like receptor (TLR) 4 but Not TLR3 Requires the p65 Subunit of NF-κ* , 2003, Journal of Biological Chemistry.

[49]  Martin M Holtmann.  RDP-58 (SangStat Medical). , 2003, IDrugs : the investigational drugs journal.

[50]  M. Dougados,et al.  Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. , 2003, The New England journal of medicine.

[51]  J. O’Shea,et al.  Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor , 2003, Science.

[52]  R. Herbst,et al.  Gefitinib: current and future status in cancer therapy. , 2003, Clinical advances in hematology & oncology : H&O.

[53]  L. O’Neill.  Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. , 2003, Current opinion in pharmacology.

[54]  J. Rigas,et al.  P-611 Final results from a phase II study of erlotinib (TarcevaTM) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy , 2003 .

[55]  A. Manning,et al.  Targeting JNK for therapeutic benefit: from junk to gold? , 2003, Nature Reviews Drug Discovery.

[56]  T. Bártfai,et al.  A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  A. Bowie,et al.  The Toll-IL-1 receptor adaptor family grows to five members. , 2003, Trends in immunology.

[58]  Guo-Ping Zhou,et al.  Triggering the Interferon Antiviral Response Through an IKK-Related Pathway , 2003, Science.

[59]  E. Lubberts.  The role of IL-17 and family members in the pathogenesis of arthritis. , 2003, Current opinion in investigational drugs.

[60]  S. Kushwaha,et al.  Transplant immunosuppressant agents and their role in autoimmune rheumatic diseases , 2003, Current opinion in rheumatology.

[61]  T. Maniatis,et al.  IKKε and TBK1 are essential components of the IRF3 signaling pathway , 2003, Nature Immunology.

[62]  H. Amemiya,et al.  Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment , 2003, Journal of Pharmacology and Experimental Therapeutics.

[63]  R. Gay,et al.  Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. , 2003, The American journal of pathology.

[64]  T. Moseley,et al.  Interleukin-17 family and IL-17 receptors. , 2003, Cytokine & growth factor reviews.

[65]  I. Haga,et al.  The Poxvirus Protein A52R Targets Toll-like Receptor Signaling Complexes to Suppress Host Defense , 2003, The Journal of experimental medicine.

[66]  M. Zeitz,et al.  Pralnacasan (vertex pharmaceuticals). , 2003, IDrugs : the investigational drugs journal.

[67]  Sophie Janssens,et al.  Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. , 2003, Molecular cell.

[68]  Michael Kracht,et al.  Transcriptional and post-transcriptional control of gene expression in inflammation. , 2002, Cytokine.

[69]  J. Saklatvala,et al.  Dexamethasone Causes Sustained Expression of Mitogen-Activated Protein Kinase (MAPK) Phosphatase 1 and Phosphatase-Mediated Inhibition of MAPK p38 , 2002, Molecular and Cellular Biology.

[70]  D. Taub,et al.  Effect of rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway. , 2002, Blood.

[71]  M. Shlomchik,et al.  Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.

[72]  O. Kassel,et al.  Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP‐1 , 2001, The EMBO journal.

[73]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[74]  Judy H. Cho,et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.

[75]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[76]  D. Underwood,et al.  Inhibition of p38 MAP Kinase , 2001 .

[77]  A. Manning,et al.  Jun N-terminal kinase in rheumatoid arthritis. , 1999, The Journal of pharmacology and experimental therapeutics.

[78]  J. Corbin,et al.  Cyclic GMP Phosphodiesterase-5: Target of Sildenafil* , 1999, The Journal of Biological Chemistry.

[79]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[80]  L. O’Neill,et al.  Signal transduction pathways activated by the IL‐1 receptor family: ancient signaling machinery in mammals, insects, and plants , 1998, Journal of leukocyte biology.

[81]  Jerry L. Adams,et al.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.

[82]  J. Hsuan,et al.  Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of hsp27 , 1994, Cell.

[83]  L Bibbs,et al.  A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. , 1994, Science.

[84]  M. Feldmann,et al.  TNF alpha--a pivotal role in rheumatoid arthritis? , 1992, British journal of rheumatology.

[85]  N. Gay,et al.  Drosophila Toll and IL-1 receptor , 1991, Nature.

[86]  G. Nabel,et al.  Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[87]  David Baltimore,et al.  Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism , 1986, Cell.

[88]  Tomohiro Watanabe,et al.  Signalling pathways and molecular interactions of NOD1 and NOD2 , 2006, Nature Reviews Immunology.

[89]  K. Fan Chung.  Phosphodiesterase inhibitors in airways disease. , 2006, European journal of pharmacology.

[90]  Tobias Gabriel,et al.  Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. , 2005, Current topics in medicinal chemistry.

[91]  K. Lehle,et al.  Predominant inhibition of interleukin-6 synthesis in patient-specific endothelial cells by mTOR inhibitors below a concentration range where cell proliferation is affected and mitotic arrest takes place. , 2005, Transplantation proceedings.

[92]  Michael Karin,et al.  The IKK NF-κB system: a treasure trove for drug development , 2004, Nature Reviews Drug Discovery.